Why Crispr Therapeutics Stock Is Up 65% So Far in 2018 [The Motley Fool]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: The Motley Fool
The gene-editing specialist has been a rare bright spot within the hard-hit biotech space this year. Here's why. Despite a marketwide downturn that's hit biotech particularly hard this year, Crispr Therapeutics ( NASDAQ:CRSP ) , a mid-cap gene-editing company, has seen its shares gain a healthy 65% over the course of 2018. Crispr's shares have even outpaced fellow CRISPR developers Editas Medicine, Inc. ( NASDAQ:EDIT ) and Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) by a wide margin. CRSP price change so far in 2018. Data source: YCharts. What's the secret to Crispr's success? While Editas and Intellia have both struggled to shake off the market's pessimism toward biotech in general, Crispr has managed to swim upstream thanks to its ability to convince regulators in both the European Union and the United States to green light its lead clinical candidate, CTX001, for human trials. Earlier this year, Crispr became the first company to initiate hu
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics' (NASDAQ:CRSP) investors will be pleased with their favorable 63% return over the last five years [Yahoo! Finance]Yahoo! Finance
- 3 Magnificent Stocks That Could Double or More by 2030 [Yahoo! Finance]Yahoo! Finance
- Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $90.00 price target on the stock.MarketBeat
- CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/21/24 - Beat
CRSP
Sec Filings
- 4/15/24 - Form 144
- 4/10/24 - Form SC
- 4/9/24 - Form ARS
- CRSP's page on the SEC website